KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Tax ProvisionsTax Rate
Others
Ratios

BioNTech SE (BNTX) EBITDA (2018 - 2025)

Historic EBITDA for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to -$54.8 million.

  • BioNTech SE's EBITDA fell 57547.68% to -$54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 111.18%. This contributed to the annual value of -$1.4 billion for FY2024, which is 28906.84% down from last year.
  • As of Q3 2025, BioNTech SE's EBITDA stood at -$54.8 million, which was down 57547.68% from -$567.2 million recorded in Q2 2025.
  • BioNTech SE's 5-year EBITDA high stood at $5.6 billion for Q3 2021, and its period low was -$1.0 billion during Q2 2024.
  • Over the past 5 years, BioNTech SE's median EBITDA value was $566.2 million (recorded in 2023), while the average stood at $1.6 billion.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 184653558396.13% in 2021, then plummeted by 57547.68% in 2025.
  • Over the past 5 years, BioNTech SE's EBITDA (Quarter) stood at $5.4 billion in 2021, then crashed by 37.51% to $3.4 billion in 2022, then plummeted by 83.15% to $566.2 million in 2023, then crashed by 71.95% to $158.8 million in 2024, then tumbled by 134.53% to -$54.8 million in 2025.
  • Its EBITDA stands at -$54.8 million for Q3 2025, versus -$567.2 million for Q2 2025 and -$561.8 million for Q1 2025.